Floatz logo

2-OXAANDROSTAN-3-ONE, 17-HYDROXY-17-METHYL-, (5.ALPHA.,17.BETA.)-

Cancer Of Unknown Primary Site

Wake Forest University Health SciencesSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Cancer Of Unknown Primary Site cohort.

Asset / SponsorPhaseRating
Amifostine
M.D. Anderson Cancer Center
Phase 4BBB
Nepenthe
M.D. Anderson Cancer Center
Phase 4BBB
Etoposide
University of California, Davis
Phase 2/3BBB
Dexasone
Alliance for Clinical Trials in Oncology
Phase 3BBB
Xaliplatin
Alliance for Clinical Trials in Oncology
Phase 2BBB

View all 50 →

Same molecule, other indications

2-OXAANDROSTAN-3-ONE, 17-HYDROXY-17-METHYL-, (5.ALPHA.,17.BETA.)- is also rated in:

HIV wasting syndromeDormant
BB
Indicative · Phase 4
69 / 100
View asset →
Turner syndromeDormant
B
Indicative · Phase 2
57 / 100
View asset →
Fanconi anemiaDormant
CC
Indicative · Phase 1
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →